Lacosamid Beta (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing hyperexcitable neurons, it reduces repetitive firing and the spread of epileptic activity, thereby contributing to seizure suppression.

The specific dose of Lacosamid Beta is determined by the prescribing clinician based on the individual’s medical condition, age, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lacosamide during pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Lacosamid Beta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacosamide’s mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide an alternative for patients who have inadequate response or tolerability issues with other agents, though individual efficacy and safety profiles vary.

Lacosamid Beta should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Lacosamid Beta is taken orally, usually as a tablet. The exact dosing schedule—such as once or twice daily—depends on the prescriber’s recommendation and should be taken with or without food as directed.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, potential suicidal thoughts or behaviors, severe skin reactions, and significant liver enzyme elevations. Patients should be monitored regularly for these events, especially during treatment initiation.

Lacosamid Beta is contraindicated in individuals with known hypersensitivity to lacosamide or any of its excipients. Caution is also advised for patients with severe cardiac conduction disorders, uncontrolled arrhythmias, or those taking medications that markedly affect its metabolism.